Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Iranian Journal of Cancer Prevention. 2015; 8 (4): 27-32
en Inglés | IMEMR | ID: emr-173819

RESUMEN

Background: Cervical cancer remains to be a major health problem and cancer-related cause of death among women in developing countries such as Iran where the most cases are diagnosed in locally advanced stage


Objectives: This cross sectional-analytic study aims to report outcome 154 patients with carcinoma of cervix were treated with external beam radiation therapy [EBRT] and high-dose-rate [HDR] brachytherapy with cobalt 60 [Co-6o] remote after loading system


Patients and Methods: A total of 154 patients with the international federation of gynecologist and oncologist [FIGO] stages I-IVA with histopathologically confirmed carcinoma of cervix, followed by the radiation-oncology ward of Shohada-e-Tajrish Hospital in Tehran, Iran, between February 2008 and March 2015. They were completed their scheduled EBRT and HDR brachytherapy with Co-60 remote after loading system. Out of this, 132 patients completed their standard follow up protocol. They were analyzed for 3-year disease-free survival [DFS], 3-year overall survival [OS] incidence of acute and late complications for HDR brachytherapy


Results: Fourteen patients [9.1 %] were in stage I [FIGO classification], 8 [5.2%] were in stage IIA, 26 [16.9%] were in stage IIB, 100 [64.9%] were in stage III, and 6 [3.9 %] were in stage IVA. The follow up duration was between 6 - 60 months with a median of 38 months. Overall rectal and bladder treatment toxicity rates were 33.7%. The 3-year DFS rate was 85.7%, 70.7 %, 41% and 16.6% for stages I, II, III, IVA respectively. Favorable prognostic factors in univariate and multivariate analysis were early stage, tumor size < 4 cm [after adjusting for the residual disease after radiation], no pelvic lymph node involvement and 1 week Gap between EBRT and HDR brachytherapy in 3-year DFS [P = 0.001, P = 0.012, P = 0.005, P = 0.005, respectively]. The 3-year OS rate was 85.7%, 76.4%, 42%, and 33.3% for stages I, II, III, and IVA, respectively. Favorable prognostic factors in univariate and multivariate analysis were early stage, tumor size < 4 cm, no pelvic lymph node involvement, 1 week gap between EBRT and HDR brachytherapy and no distant metastasis [during the follow up] in 3-year OS [P = 0.001, P = 0.002, P = 0.002, P = 0.002, P = 0.001, respectively]


Conclusions: HDR brachytherapy with Co-60 remote after loading system was successful and it showed HDR brachytherapy in treating patients with carcinoma of cervix was effective after EBRT with acceptable rectal and bladder complications


Asunto(s)
Humanos , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Braquiterapia , Radioisótopos de Cobalto , Estudios Transversales , Supervivencia sin Enfermedad , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA